GlassScriptPhysician profile
James Hurlburt
NPI 1538429725
$8,087.13
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,196 · 2020: $2,034 · 2021: $2,934 · 2022: $1,894 · 2023: $29.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $29.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $29.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,053.73 | 2019-2022 | |
| Abbvie INC. | $1,000.25 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $679.16 | 2019-2022 | |
| Amgen INC. | $568.03 | 2019-2022 | |
| Glaxosmithkline, LLC. | $501.84 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $488.65 | 2019-2022 | |
| Lilly USA, LLC | $425.62 | 2019-2022 | |
| Amarin Pharma, INC. | $304.36 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $298.48 | 2019-2022 | |
| Allergan, INC. | $266.83 | 2019-2020 | |
| Mylan Specialty L.P. | $249.31 | 2020-2023 | Yupelri |
| Daiichi Sankyo INC. | $230.74 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $229.41 | 2020-2022 | |
| Astellas Pharma US INC | $215.64 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $208.08 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hurlburt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.